NeuroSense Therapeutics Ltd. NRSNW
As ofNov 16, 2026, 10:22 AM EST
- YTD
- +17.86%
- 1 year
- +17.86%
- Market cap
- 135.67K
- EPS (ttm)
- -0.935
- YTD return
- +17.86%
- 1-year return
- +17.86%
- Free cash flow
- -6.63M
- Total cash
- 1.21M
- Volume
- 6
- Open
- 0.0055
- Previous close
- 0.0056
- Day's range
- 0.0055 – 0.0055
- 52-week range
- 0.0055 – 0.0056
- Beta
- 1.56
Key statistics
- Total debt
- 36.00K
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- neurosense-tx.com
News
Your note
Sign in to keep a note on NRSNW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Clear Street LLC | 3.56% | 65,759 | 29.59K | Sep 29, 2024 |
| Citadel Advisors Llc | 1.37% | 25,274 | 11.37K | Sep 29, 2024 |
| Warberg Asset Management LLC | 1.09% | 20,201 | 9.09K | Sep 29, 2024 |
| UBS Group AG | 0.01% | 200 | 89 | Sep 29, 2024 |
